ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,841Medicare Part D Prescriptions Filled, Including Refills

Rank: 10 out of 251

$548K Total Retail Price of All Prescriptions

Rank: 11 out of 251

453 Patients Receiving at Least One Drug in Part D
70%Patients 65 Years and Older
38% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Hampshire
Lower avg

Schedule Two
Controlled Substances

19% of this provider’s 453 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

11% of this provider’s 453 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 6,018 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$62 was the average price of a prescription from this provider, compared to $64 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Hampshire
SIMVASTATIN 401 302 1 1
AMLODIPINE BESYLATE 360 278 2 4
LISINOPRIL 301 220 3 2
OMEPRAZOLE 252 166 4 5
HYDROCODONE-ACETAMINOPHEN 234 111 S3 5 18
HYDROCHLOROTHIAZIDE 232 163 6 9
METFORMIN HCL 226 140 7 10
METOPROLOL TARTRATE 195 150 8 7
LEVOTHYROXINE SODIUM 182 114 9 3
ATORVASTATIN CALCIUM 176 140 10 8
METOPROLOL SUCCINATE 175 131 11 13
CRESTOR 174 115 12 21
GLIMEPIRIDE 161 130 13 62
FUROSEMIDE 159 113 14 6
PRAVASTATIN SODIUM 136 113 15 14
GABAPENTIN 136 87 15 16
OXYCODONE HCL 111 36 S2 17 30
TRAMADOL HCL 111 40 17 24
ALENDRONATE SODIUM 108 95 19 39
ALLOPURINOL 104 93 20 34
OXYCODONE HCL-ACETAMINOPHEN 96 0 S2 21 101
LOSARTAN POTASSIUM 88 72 22 17
NEXIUM 87 30 23 28
OXYCODONE-ACETAMINOPHEN 85 38 S2 24 55
ATENOLOL 84 74 25 12
ZOLPIDEM TARTRATE 82 35 26 19
CYCLOBENZAPRINE HCL 82 22 R 26 57
PANTOPRAZOLE SODIUM 82 74 26 20
WARFARIN SODIUM 78 53 29 11
SERTRALINE HCL 76 61 30 22
DIOVAN 72 62 31 23
PROAIR HFA 72 47 31 42
SPIRIVA 67 47 33 37
LISINOPRIL-HYDROCHLOROTHIAZIDE 65 59 34 48
METHADONE HCL 60 0 S2 35 87
RANITIDINE HCL 60 39 35 35
COMBIVENT 60 50 35 118
FLUTICASONE PROPIONATE 58 51 38 38
CYMBALTA 58 33 38 47
PREDNISONE 57 45 40 27
KLOR-CON M20 57 57 40 45
CLOPIDOGREL 55 47 42 60
CITALOPRAM HBR 53 30 43 15
ZETIA 53 41 43 73
CELEBREX 52 39 45 81
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 25, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.